Amyris Inc (NASDAQ:AMRS) was the target of a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 9,016,318 shares, a decline of 39.1% from the April 15th total of 14,805,158 shares. Based on an average daily volume of 3,798,971 shares, the days-to-cover ratio is presently 2.4 days. Approximately 33.4% of the company’s stock are short sold.

In other news, Director L John Doerr purchased 2,832,440 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The shares were acquired at an average cost of $5.12 per share, for a total transaction of $14,502,092.80. Following the completion of the acquisition, the director now owns 5,532 shares in the company, valued at $28,323.84. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Frank Kung purchased 913,529 shares of the business’s stock in a transaction that occurred on Monday, April 29th. The shares were purchased at an average price of $4.76 per share, for a total transaction of $4,348,398.04. Following the completion of the acquisition, the director now owns 3,599 shares of the company’s stock, valued at approximately $17,131.24. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 10,478,338 shares of company stock worth $38,172,390. 21.80% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMRS. SG Americas Securities LLC purchased a new position in Amyris in the first quarter valued at about $28,000. American Financial Advisors LLC purchased a new position in Amyris in the first quarter valued at about $33,000. Pinnacle Wealth Management Advisory Group LLC purchased a new position in Amyris in the first quarter valued at about $38,000. Jane Street Group LLC purchased a new position in Amyris in the fourth quarter valued at about $48,000. Finally, Caption Management LLC purchased a new position in Amyris in the fourth quarter valued at about $50,000. Hedge funds and other institutional investors own 33.29% of the company’s stock.

AMRS opened at $4.02 on Friday. The stock has a market capitalization of $322.17 million, a price-to-earnings ratio of -1.59 and a beta of 0.86. Amyris has a twelve month low of $1.87 and a twelve month high of $9.28.

Amyris (NASDAQ:AMRS) last released its earnings results on Monday, March 18th. The biotechnology company reported ($1.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.44 by ($1.51). The business had revenue of $19.36 million for the quarter, compared to analysts’ expectations of $98.52 million. The firm’s revenue was down 76.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.61 EPS. As a group, equities research analysts anticipate that Amyris will post -0.31 EPS for the current year.

A number of research analysts have weighed in on the stock. BidaskClub upgraded shares of Amyris from a “sell” rating to a “hold” rating in a research note on Thursday, April 18th. HC Wainwright set a $11.00 target price on shares of Amyris and gave the company a “buy” rating in a research note on Tuesday, February 5th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Amyris currently has an average rating of “Buy” and a consensus target price of $9.50.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://theolympiareport.com/2019/05/25/amyris-inc-amrs-short-interest-update.html.

Amyris Company Profile

Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.

Featured Article: What are benefits of a growth and income fund?

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.